You are on page 1of 14

bs_bs_banner

Lead Article

Nutraceuticals and their preventive or potential therapeutic value in Parkinson's disease


Jianfei Chao, Yen Leung, Mingfu Wang, and Raymond Chuen-Chung Chang
Parkinson's disease (PD) is the second most common aging-related disorder in the world, after Alzheimer's disease. It is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta and other parts of the brain, leading to motor impairment, cognitive impairment, and dementia. Current treatment methods, such as L-dopa therapy, are focused only on relieving symptoms and delaying progression of the disease. To date, there is no known cure for PD, making prevention of PD as important as ever. More than a decade of research has revealed a number of major risk factors, including oxidative stress and mitochondrial dysfunction. Moreover, numerous nutraceuticals have been found to target and attenuate these risk factors, thereby preventing or delaying the progression of PD. These nutraceuticals include vitamins C, D, E, coenzyme Q10, creatine, unsaturated fatty acids, sulfur-containing compounds, polyphenols, stilbenes, and phytoestrogens. This review examines the role of nutraceuticals in the prevention or delay of PD as well as the mechanisms of action of nutraceuticals and their potential applications as therapeutic agents, either alone or in combination with current treatment methods.
2012 International Life Sciences Institute

INTRODUCTION Parkinsons disease (PD) is regarded as the second most prevalent aging-related neurodegenerative disorder after Alzheimers disease (AD), aecting approximately 0.017% of people between the ages of 50 and 59 years, with a median onset age of around 60 years. Aging is undoubtedly a major risk factor of PD, as the incidence of PD jumps to approximately 0.093% in people between the ages of 70 and 79 years. In people over 70 years of age, the number of men diagnosed with PD is about 1.5 times higher than that of women.1

Environmental toxins and exposure to pesticides have also been reported to contribute to PD morbidity. Examples of environmental toxins include 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine (MPTP), toluene, carbon disulde, and cyanide,2 while examples of pesticides include paraquat, organophosphates, and rotenone.3 MPTP exposure has been found to induce both loss of dopaminergic neurons and clinical parkinsonism. Similarly, rotenone and paraquat, when applied to experimental animals, have been found to induce loss of dopaminergic neurons and typical parkinsonism.4 As potential etiological factors of PD, environmental

Aliations: J Chao is with the Laboratory of Neurodegenerative Diseases, Department of Anatomy, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China, and the School of Biological Sciences, Faculty of Science, The University of Hong Kong, Pokfulam, Hong Kong SAR, China. Y Leung is with the Laboratory of Neurodegenerative Diseases, Department of Anatomy, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China. M Wang is with the School of Biological Sciences, Faculty of Science, The University of Hong Kong, Pokfulam, Hong Kong SAR, China. RC-C Chang is with the Laboratory of Neurodegenerative Diseases, Department of Anatomy, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China, and the Research Centre of Heart, Brain, Hormone and Healthy Aging, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China, and the State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Pokfulam, Hong Kong SAR, China. Correspondence: RC-C Chang, Rm. L1-49, Laboratory Block, Faculty of Medicine Building, Department of Anatomy, LKS Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Hong Kong SAR, China. E-mail: rccchang@hku.hk. Phone: +852-2819-9127. Fax: +852-2817-0857. Key words: dietary supplement, neuroprotection, nutraceuticals, Parkinson's disease
doi:10.1111/j.1753-4887.2012.00484.x Nutrition Reviews Vol. 70(7):373386 373

Table 1 Gene identication in Parkinson's disease. Gene/protein Clinical features of gene/ protein expression SNCA/alphaEarly-onset parkinsonism, synuclein onset between 40 and 49 years of age, Lewy bodies, dementia UCHL1/ubiquitin carboxy-terminal hydrolase 1 LRRK2/leucine-rich repeat kinase 2 Onset between 50 and 59 years of age, typical PD very rare Onset between 60 and 69 years of age, Lewy bodies, Tau pathology, typical PD

Functions of the protein Mainly unknown, possibly synaptic vesicle tracking

Pathogenic mutations A53T, A30P, and E46K, all of which may promote aggregation; Lewy body and Alzheimer plaque component; protobrils (toxic)

Removal of polyubiquitin

Mainly unknown; found G2019S, most common in primarily in the cytoplasm North African, Ashkenazim, but also associated with the and Spanish populations outer mitochondrial membrane HTRA2/serine Typical PD very rare Mainly unknown; primarily protease localized in the endoplasmic reticulum and mitochondria PRKN/parkin Early onset, usually before age Ubiquitin E3 ligase attaches Over 70 mutations identied 30, without Lewy bodies, short ubiquitin peptide rarely juvenile, slow chains to a range of progression proteins, likely to mark degradation PINK1/PTEN-induced Early onset at 3040 years of Mitochondrial kinase; putative kinase 1 age, slow progression, modulates mitochondrial psychiatric features dynamics common DJ-1/DJ-1 Early onset at 3040 years of Possible a typical L166P, M261, and a variety of age, rarely juvenile peroxiredoxin, may be other candidates involved in apoptosis ATP13A2/lysosomal Early onset, dementia, Mainly unknown; an ATPase Nonsense mutation found to ATPase pyramidal features, located in the lysosome be associated with pallidal supranuclear gaze palsy degeneration GBA/glucocerebrosidase Typical PD Mainly unknown: primarily located in lysosome

chemicals may interact with gene expression and modulate expression of mutated genes in humans. Thus, genetic analysis of patients with PD has become an important research theme in PD. A small percentage of PD cases are attributed to single gene defects. Thus far, genetic studies have identied more than 10 genes that cause familial PD. The functions of these genes, along with associated clinical features, are listed in Table 1.5,6 PATHOLOGICAL FACTORS ASSOCIATED WITH PARKINSON'S DISEASE PD is dened pathologically by the progressive loss of dopaminergic neurons in the substantia nigra (SN) pars compacta accompanied by the presence of intracellular Lewy bodies. Parkinsonism, along with parkinsonian syndrome, should be distinguished from PD. Parkinsonism is
374

a term that refers only to the clinical symptoms of PD, such as the occurrence of tremors and dementia, but bears no implication of disease mechanism, while PD refers to the pathology described above. The exact mechanisms of PD are not yet fully understood, although several factors, including protein misfolding, oxidative stress, and mitochondrial dysfunction, have been reported. Numerous studies indicate a causal role of misfolded proteins such as beta-amyloid and a-synuclein in AD and PD, as misfolding results in accumulation of the protein either extra- or intracellularly.7 If chaperones fail to restore misfolded proteins, the ubiquitin proteasome system and autophagy will subsequently clear the misfolded proteins.8 Both mutation and aggregation of a-synuclein can cause parkinsonism, but mutation of a-synuclein is rarely found in patients with sporadic PD.9 Unique biochemical features of the SN render it more vulnerable to oxidative stress when compared with
Nutrition Reviews Vol. 70(7):373386

other parts of the brain. In particular, the SN has a uniquely high iron content. Dopamine can be oxidized by monoamine oxidase B (MAO-B) to form hydroxyl free radicals in the presence of ferrous iron. The combined eects result in enormous amounts of hydroxyl free radicals, leading to severe damage of the dopaminergic neurons of the SN. These pathological events suggest that oxidative stress is the most important pathological factor for the initiation and progression of PD.10 Indeed, the SNs of PD patients have been found to show elevated levels of oxidative stress.Youdim and Riederer11 reported that lipid-peroxidation-promoting substances such as ferrous iron are found in high levels in the SN of postmortem PD brain, concomitant with decreased levels of antioxidants. Similar results were obtained by a study investigating the level of hydroxynonenal adducts, which are products of lipid peroxidation.12 Elevated levels of lipid peroxidation have been found in the SN region of the brain and in erythrocytes from blood samples of PD patients.13 Numerous studies suggest that impairment of mitochondrial function is also involved in the pathogenesis of PD. Mitochondrial function is closely related to oxidative stress because mitochondria produce ATP by oxidative phosphorylation. During ATP production, mitochondria may produce superoxide radicals as by-products. Defects of the electron transport chain can result in the failure of energy metabolism, increased free-radical-mediated damage, and activation of downstream cell death pathways.1416 In the early 1980s, contamination of MPTP in heroin was found to cause parkinsonism in drug abusers.17 Since then, MPTP has been used extensively to induce neurotoxic experimental PD. The active form of MPTP is metabolized in the mitochondria of astrocytes in the SN to form MPP+ and is then transferred to inhibit complex I of the electron transport chain in neurons, leading to ATP depletion and accumulation of reactive oxygen species (ROS).18 Elevated mitochondrial ROS levels result in mitochondrial DNA mutations, proteins/ lipids perturbation and can further aect redox signaling pathways.19 Another widely used neurotoxin, 6-OHDA, induces pathological events similar to those seen in experimental PD.20 Numerous studies have shown that food components and nutritional substances can prevent or delay the progression of PD by protecting mitochondrial function.21 This further supports the role of mitochondrial impairment as a major pathological factor in PD.2224 TREATMENT FOR PATIENTS WITH PARKINSON'S DISEASE Although PD was rst diagnosed almost two centuries ago, a cure has yet to be found. Current treatments are
Nutrition Reviews Vol. 70(7):373386

mainly categorized into symptom-relieving drugs and surgical treatments. L-dopa, dopamine agonists (pramipexole, bromocriptine, pergolide, ropinirole, piribedil, cabergoline, apomorphine, and lisuride) and MAO-B inhibitors (selegiline and rasagiline) are examples of symptom-relieving drugs, while deep brain stimulation, implantation of embryonic dopaminergic cells, and gene therapy have been applied as surgical treatments for PD patients. These treatments only aim to improve the quality of life by attenuating motor or nonmotor symptoms of PD. As the global population ages, the need to develop a disease-modifying drug for PD is becoming increasingly urgent. Existing PD treatments have undesirable eects. For example, L-dopa, a commonly used symptom-relieving drug for PD, has various side eects because 9599% of it is metabolized to dopamine in the body in places other than the dopaminergic neurons in the SN. For this reason, dopa decarboxylase inhibitors (e.g., carbidopa and benserazide) and COMT enzyme inhibitors (e.g., tolcapone and entacapone) are prescribed in combination with L-lopa to enhance its eect. Discontinuous delivery of L-dopa has been another limitation of the treatment. Novel delivery methods of L-dopa seek to overcome this, such as an intravenous infusion delivery approach and a transdermal delivery system, both of which have been applied in clinical settings for the past two decades.5,6 POTENTIAL NEUROPROTECTIVE EFFECTS OF NUTRACEUTICALS Combining the words nutrition and pharmaceutical, the word nutraceuticals refers to foods or food products that reasonable clinical evidence suggests may provide health and medical benets, including for prevention and treatment of disease. Such products may be categorized as dietary supplements, specic diets, herbal products, or processed foods such as cereals, soups, and beverages. Dietary supplements can be extracts or concentrates and are found in many forms, including tablets, capsules, liquids, and powders. Vitamins, minerals, herbs, or isolated bioactive compounds are only a few examples of dietary ingredients in the products. Functional foods are designed as enriched foods close to their natural state, providing an alternative to dietary supplements manufactured in liquid or capsule form. It is generally accepted that neuroprotection prevents neurons from succumbing to damages by dierent insults. Nutraceuticals can provide neuroprotection via a wide range of proposed mechanisms, such as scavenging of free radicals and ROS, chelation of iron, modulation of cell-signaling pathways, and inhibition of inammation.25 Neuroprotection can prevent and impede the progression of PD as well as the loss of dopaminergic neurons. In the
375

following section, the neuroprotective eects of selected dietary supplements and functional foods are reviewed and discussed. In addition, several relevant therapeutic eects are evaluated.

Mechanisms of action Antioxidant vitamins have a putative role in reducing the oxidative damage in SN dopaminergic neurons in progressive disease.34 Vitamin C has been proven in vitro to be a major free-radical scavenger in the cytosol, while tocopherols act as a major lipid-soluble antioxidant to prevent lipid peroxidation in membranes. Both vitamins also act in a synergistic manner whereby vitamin C can reduce oxidized vitamin E to restore its antioxidative function.35 Thus, supplemental vitamins can be useful in prevention or in delaying progression of PD by reducing oxidative stress. VITAMIN D Potential neuroprotective eects In 2007, Newmark and Newmark36 proposed that vitamin D deciency had a signicant role in the development and progression of PD. Vitamin D has been found to attenuate 6-OHDA-induced and MPP+-induced neurotoxicity, while vitamin D receptor knockout mice show motor defect. Moreover, the levels of vitamin-D-binding protein have been proposed as one of the biomarkers for PD.3739 It has been debated that vitamin D inadequacy in PD patients is a result of reduced physical activity and exposure to sunlight, rather than a causal factor in PD progression. However, the results of a recent longitudinal study by Knekt et al. 40 oppose this view. A large sample of Finnish adults aged 30 years or older was selected from 1978 to 1980, and blood serum samples were examined. Occurrences of PD were recorded in a 29-year follow-up period. In 2002, serum levels of vitamin D were measured, and results showed that subjects with higher serum vitamin D levels had a signicantly lower risk of developing PD.40 These data suggest that vitamin D levels could be used as a predictive indicator of PD risk. Mechanisms of action The SN is one of the regions in the brain containing high levels of vitamin D receptors and 1a-hydroxylase,40 the enzyme responsible for the biological activation of vitamin D. Hence, vitamin D may be involved in a number of signaling pathways, and several mechanisms may be responsible for the neuroprotective eects of vitamin D. In animal studies, vitamin D was found to upregulate glial cell line-derived neurotrophic factor levels.37 Glial cell line-derived neurotrophic factor has been shown to be antiparkinsonian in animal and in vitro studies. It can
Nutrition Reviews Vol. 70(7):373386

ANTIOXIDANT VITAMIN SUPPLEMENTS (VITAMINS C AND E) Antioxidant vitamin supplements such as vitamin C, vitamin E (or tocopherol), and beta-carotene are common forms of nutraceuticals.26 A cross-sectional study found that vitamin E supplements are popular in PD patients, while epidemiological studies have shown that consuming foods rich in vitamins C and E are associated with a lower risk of developing PD.27 However, it should be noted that these studies are not specic to individual antioxidant nutrients; rather, it is the foods rich in these nutrients that are studied. Potential neuroprotective eects An early study has suggested a protective eect of these two antioxidative vitamins on PD patients.28 In an openlabel trial, high doses of vitamins C and E were administered to patients in the early stage of PD. It was found that patients who took antioxidant vitamins had a 2.5- to 3-year delay in receiving L-dopa treatment compared with those of Dr. CM Tanner, who did not treat patients with vitamins, as reported by Fahn.28 Treatment was delayed from 40 months to 72 6.5 months for those PD patients who started taking the vitamins before 54 years of age, and from 24 months to 63 3.9 months for those who started the vitamins after 54 years of age. Although the placebo eect might be at play here, the delay of onset of parkinsonism was remarkably signicant. Another report showed that vitamin C at 10 mM can reduce neurotoxicity elicited by dopamine metabolism.29 An important double-blind and placebo-controlled clinical study, the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) by the Parkinson Study Group, showed that vitamin E supplementation was not able to delay the need for introducing L-dopa therapy.30 However, as pointed out in a commentary for this study, the trial did not exclude the possibility that nutritional supplements may delay progression of PD by preventing loss of dopaminergic neurons.31 A contradicting report showed that 9.8 IU/day of vitamin E intake from the diet may be benecial.32 A meta-analysis produced similar results, showing that dietary intake of vitamin E in moderate amounts may be neuroprotective. High intake of vitamin C in the form of a supplement was not signicantly protective, with no association found between vitamin C intake and risk of PD.33
376

promote the outgrowth of dopaminergic axons in striatal neurons in a region-specic manner and can even rescue SN neurons from 6-OHDA toxicity.41 In addition, vitamin D can increase glutathione levels, regulate calcium homeostasis, exert anti-apoptotic and immunomodulatory eects, reduce nitric oxide synthase, and regulate dopamine levels.42,43 COENZYME Q10 Potential neuroprotective eects Coenzyme Q10 (CoQ10 or ubiquinone) is a popular commercially available dietary supplement (Figure 1). It has been recognized as a neuroprotective agent in the prevention and treatment of PD.44 CoQ10 has been demonstrated to prevent the loss of dopaminergic neurons in MPTP-induced neurotoxicity and parkinsonism.45,46 In a placebo-controlled, randomized, double-blind study involving 80 patients with early-stage PD, patients in the treatment group were found to have less disability, as evaluated for over 16 months using the Unied Parkinson Disease Rating Scale. It should be noted that the eects of CoQ10 were dose dependent. The group receiving 1,200 mg/day, which was the highest dose among the different groups, exhibited a 44% reduction in functional decline compared with the placebo group.47 In another study, a mild symptomatic benet was observed using the Farnsworth-Munsell 100 Hue test. The authors suggested that an oral supplement of CoQ10 could achieve a moderate benecial eect, but not a great neuroprotective

eect.48 From these reports, there is no conclusion about whether the eect of CoQ10 on PD is neuroprotective or merely symptom relieving. Mechanisms of action CoQ10 is a fat-soluble and vitamin-like quinone found abundantly in liver and the brain.49 CoQ10 is particularly relevant to mitochondrial dysfunction because of its unique electron-accepting property, which allows it to bridge mitochondrial complex I with other complexes. CoQ10 plays an important role in maintaining proper transfer of electrons in the electron transport chain of mitochondria and, thus, in the production of ATP as well. As a result, CoQ10 has a protective eect on dopaminergic neurons in the SN. In addition, it is a potent antioxidant and can exert its antioxidant eect by reducing the oxidized form of alpha-tocopherol,50 which is important in the prevention of lipid peroxidation. CREATINE Potential neuroprotective eects Creatine has also been investigated for its possible role in the treatment and prevention of PD (Figure 1). In a study using MPTP in a PD mouse model, a diet supplement of 1% creatine reduced loss of dopaminergic neurons in the SN.51 A placebo-controlled and randomized pilot trial for a 2-year period showed that creatine can improve mood and reduce the dosages required for dopaminereplacement therapy in the treated group.52 Mechanisms of action Creatine is considered to be neuroprotective due to its ability to counter ATP depletion by increasing intracellular phosphocreatine levels.51 Phosphocreatine is a key player in the maintenance of ATP levels, which in turn are important in synaptic activity and skeletal muscle functions.53,54 UNSATURATED FATTY ACIDS Potential neuroprotective eects While unsaturated fatty acids were reported to reduce the risk of developing PD,55 results from past epidemiological and retrospective studies were inconsistent. To study the relationship, a prospective study was conducted in two cohorts, the Health Professional Follow-up Study and the Nurses Health Study.56 The authors concluded that if
377

Figure 1 Chemical structure of (a) coenzyme Q10 and (b) creatine.


Nutrition Reviews Vol. 70(7):373386

saturated fatty acids are replaced by polyunsaturated fatty acids (PUFAs), the risk of developing PD may be reduced. In another large prospective population-based cohort study, the Rotterdam Study, the authors investigated the relationship between dietary unsaturated fatty acids and the risk of developing PD.55 In contrast to the previous study, they showed no relationship between the level of saturated fatty acids and the risk of developing PD. In addition to the above studies, the results of a recent investigation on omega-3 PUFAs suggest a neuroprotective eect of omega-3 PUFAs against dopamine loss and an inhibitory eect against the formation of dihydroxyphenylacetic acid in MPTP-induced parkinsonism in mice.57 This positive result should encourage future studies on the possible mechanism of PUFAs. Mechanisms of action PUFAs such as linoleic acid, alpha-linolenic acid, and docosahexaenoic acid can be components of cell membrane and precursors of signaling molecules.58 Some of these PUFAs cannot be synthesized in the human body and must be obtained from food. Monounsaturated fatty acids (MUFAs) can also reduce cholesterol and triacylglycerides in plasma.59 Impaired brain function is strongly associated with deciency of MUFAs and PUFAs. Endogenous cannabinoids derived from MUFAs are important modulators for dopaminergic neurons in the basal ganglia.60 A report has shown that fatty acid composition in the brain is highly correlated with the intake of dietary fatty acids.61 All these facts justify further study of the relationship between the intake of unsaturated fatty acids and the risk of developing PD. NATURAL SOURCES OF L-DOPA Potential neuroprotective eects To date, natural L-dopa has been found in several plants belonging to Mucuna genus, such as Mucuna pruriens (velvet bean or mucuna, the seeds of which, in 1937, were found to contain L-dopa), Stizolobium deeringianum, and Vicia faba (broad bean, in which L-dopa was identied in 1913). M. pruriens (called atmagupta in India) is a climbing legume endemic in tropical regions that include India and Central and South America. The plant has been documented in Ayurvedic medicine to treat a neurological disorder bearing symptoms similar to those of PD and up to 10% of the plants volume is L-dopa.62 In recent years, velvet bean seed extract has been used for the treatment of PD in India.63 Several open-label studies with sample sizes ranging between 18 and 60 patients prescribed mucuna seed
378

powder extract at mean doses of 45 g/day (containing about 1,500 mg L-dopa). Signicant improvements in parkinsonism were reported and better tolerability was found compared with standard L-dopa treatment alone.6466 In a recent double-blind study involving eight PD patients, the anti-Parkinsonian eect, tolerability, and L-dopa pharmacokinetic prole were compared between the mucuna seed formulation and the commercial L-dopa.67 The results showed that the eects of 30 g of M. pruriens formulation were superior to those of the standard single doses of 200/50 mg L-dopa/carbidopa. The bean powder enabled a more rapid onset of action in patients and had a slightly longer duration of therapeutic response. Moreover, severe dyskinesia or peripheral dopaminergic adverse events were not found in the mucuna-treated patients. It is suggested that the mucuna formulation may have greater bioavailability, perhaps as a result of synergistic properties of dierent compounds in the seed extract. Mechanisms of action Most in vitro studies on natural L-dopa sources focus on mucuna. In 2004, Manyam et al. 68 showed that mucuna seed powder contained signicant amounts of two neuroprotective agents, namely nicotine adenine dinucleotide (NADH) and CoQ10. Both agents protect neurons against 6-OHDA toxicity by counteracting the inhibition of mitochondrial complex I activity. NADH is also known to increase dopamine levels via the upregulation of tyrosine hydrolase. Mucuna seed powder has also been found to protect neurons against plasmid DNA and genomic DNA damage caused by a combination of L-dopa and divalent copper ions.69,70 Mucuna seed powder protects neurons against this type of damage by chelating the divalent copper ions present, preventing them from interacting with L-dopa to produce the free radicals that will damage DNA molecules.69

POLYPHENOLIC COMPOUNDS Polyphenolic compounds, or polyphenols, are products of secondary plant metabolism and are widely distributed in the plant kingdom. Polyphenolic compounds refer to a range of substances that possess an aromatic ring bearing more than one hydroxyl group. More than 8,000 phenolic structures have been identied. Polyphenols are generally divided into hydrolyzable tannins (gallic acid esters of glucose and other sugars) and phenylpropanoids, such as lignins, avonoids, and condensed tannins. Polyphenols can elicit antioxidant, antiinammatory, anticarcinogenic, antimutagenic, and
Nutrition Reviews Vol. 70(7):373386

antithrombotic eects.71 The neuroprotective eects of the major polyphenolic compounds in green tea, black tea, coee, curry, and Scutellaria baicalensis, an herb used in traditional Chinese medicine, are reviewed below. EGCG in green tea Potential neuroprotective eects. Numerous studies suggest green tea may confer health benets due to its pharmacological and biochemical properties. Epidemiological studies have shown an inverse relationship between tea consumption and the risk of developing PD. There are several experimental studies showing neuroprotective eects of green tea on MPTP-induced parkinsonism in mouse models and on cell injury in pheochromocytoma PC12 cells treated by 6-OHDA.72 Many of the benecial eects of green tea are attributed to its abundant polyphenol content, mainly the avans called catechins (Figure 2).73 There are numerous catechins found in green tea, the major ones being (-)-epicatechin (EC), (-)-epicatechin-3-gallate (ECG), (-)-epigallocatechin (EGC), and (-)-epigallocatechin-3gallate (EGCG). EGCG is the most abundant catechin.74 Levites et al. 75 summarized the biological functions of tea polyphenols and reported the following benets: free-radical scavenging and anticarcinogenic, antiinammatory, and antiangiogenic eects. Mechanisms of action. Dierent mechanisms have been proposed for the neuroprotective activity of EGCG in PD. The study conducted by Levites et al. 75 was the rst to demonstrate the neuroprotective activity of both green tea extract (0.5 and 1 mg/kg) and EGCG (2 and 10 mg/ kg) on MPTP-induced parkinsonism in animal models. It is possible that the neuroprotective eects are mediated by iron-chelating activities and free-radical-scavenging activities possessed by the catechol group. Since green tea catechins can pass through the blood-brain barrier, they can act as both ROS scavengers and iron chelators to clear the redox active ferrous iron deposited in the SN, reducing the iron-induced oxidative stress that can lead to neuronal death. The putative neuroprotective eects of green tea catechins also may be mediated via other mechanisms. Mandel et al. 73 and Levites et al. 76 summarized the neuroprotective mechanisms of green tea catechins as regulation of protein kinase C activity and induction of endogenous antioxidant defense systems. A recent experimental study using the 6-OHDA rat model of PD also suggests that green tea catechins protect the SN dopaminergic neurons through modulation of the ROS-NO pathway.77 It appears there is considerable evidence to support the putative neuroprotective eects of green tea. Nonetheless, much of the evidence was derived
Nutrition Reviews Vol. 70(7):373386

Figure 2 Chemical structure of polyphenolic compounds (a) EGCG, (b) curcuminoids, and (c) baicalein. from experimental and animal studies, while evidence from large prospective studies or case-control studies specic to green tea catechins rather than to general tea consumption is limited. In contrast to other reports showing benecial eects of green tea, the prospective cohort study of the Singapore Chinese Health Study78 showed no relationship between green tea consumption and the risk of developing PD if caeine intake was excluded. Therefore, more studies of green tea consumption in humans and the risk of developing PD are required to verify the possible protective eect of green tea. Curcuminoids in curry Potential neuroprotective eects. Curcumin (1,7-bis[4hydroxy 3-methoxy phenyl]-1,6-heptadiene-3,5-dione) is a polyphenolic avonoid that constitutes approximately 4% of turmeric, which has a long history of use in tradi379

tional Asian diets and herbal medicines (Figure 2). Curcumin is the principal curcuminoid in turmeric. The other two curcuminoids are desmethoxycurcumin and bisdesmethoxycurcumin. Curcuminoids, rather than curcumin alone, are commercially available and are generally used in experimental studies. The bioactive eects of curcuminoids have often been attributed to curcumin, as the curcumin content of curcuminoids reaches up to 80%. Mechanisms of action. Like other polyphenolic compounds such as caeic acid, EGCG, and resveratrol, curcumin is well known for its powerful antioxidant properties. Jagatha et al.79 reported that curcumin treatment of mice and of dopaminergic neurons in cell cultures attenuated oxidative stress by restoring glutathione levels, thereby protecting neurons against protein oxidation and preserving mitochondrial complex I activity. The reduction of 6-OHDA-induced neurotoxicity in MES 23.5 cells and in a rat model of PD has been attributed to the antioxidant properties of curcumin.80 In addition, curcumins direct modulation of 6-OHDA-induced nuclear factor-kappa B (NF-kB) translocation confers neuroprotective eects in dopaminergic neuronal cells of the MES 23.5 cell line.81 Curcumin has also been found to exhibit antiinammatory properties. In primary cultures of rat mesencephalic neuronal/glial cells, curcumin inhibited lipopolysaccharide (LPS)-induced morphological changes of microglia and dramatically reduced LPSinduced production of many proinammatory factors and their gene expressions. LPS-induced activation of transcription factors, such as NF-kB and activator protein-1, were also attenuated by curcumin treatment.82 In addition, curcumin has been found to prevent MPTP/MPP+-induced neurotoxicity in C57BL/6N mice, SH-SY5Y cells, and PC12 cells by targeting the JNK, the Bcl-2-mitochondria, and the ROS-iNOS (inducible nitric oxide synthase) pathways.83,84 Systemic administration of curcumin (80 mg/kg i.p.) and its metabolite tetrahydrocurcumin (60 mg/kg i.p.) signicantly reversed MPTP-induced depletion of DA and DOPAC (3,4dihydroxy phenyl acetic acid) in mice. The authors concluded that the reversion may be, in part, due to the inhibition of MAO-B activity by these compounds.85 Furthermore, both overexpression and abnormal accumulation of aggregated alpha-synuclein (AS) have been found to be closely linked to PD. Recent studies revealed that curcumin could inhibit aggregation of AS in cell-free conditions and in a cellular model of A53T-AS overexpression.86,87 Ortiz-Ortiz et al.,88 however, called for re-evaluation of the potential of curcumin as a therapeutic agent in neurodegenerative diseases. In contrast to ndings reported previously by others, Ortiz-Ortiz et al. 89 surpris380

ingly found that exposure of N27 mesencephalic cells to 10 nM curcumin synergistically enhanced paraquatmediated apoptosis. A very recent study from the same group found that exposure of rat mesencephalic cells to 10 nM curcumin induced the expression of LRRK2 in mRNA and protein levels, although there was no eect on other PD-related genes like AS and parkin. Overexpression of LRRK2 is strongly associated with the pathological inclusions found in PD. Taken together, the ndings for curcumin remain controversial and await further experimental and clinical studies. Baicalein Potential neuroprotective eects. Baicalein is a avonoid extracted from the root of Scutellaria baicalensis, a traditional Chinese herb commonly known as Huang Qin. Baicalein has been shown to be a potent antioxidant in rat primary neurons (Figure 2).90 Another study in rats also showed anti-inammatory properties of baicalein in experimental traumatic brain injury.91 Baicalein was found to be neuroprotective in several experimental models of PD, including MPTP-induced neurotoxicity and 6-OHDA-induced neurotoxicity.92,93 It has also been shown to inhibit brillization of AS.94 In a recent study, baicalein attenuated depolarization of mitochondria and proteasome inhibition in PC12 cells induced by the E46K mutation, an AS mutation linked to familial parkinsonism.95 The mechanisms underlying the neuroprotective eects of baicalein, however, remain unclear. STILBENES Stilbenes are a class of antioxidants sharing the same chemical skeleton of a diarylethene, which is a hydrocarbon consisting of a trans/cis ethene double bond substituted with a phenyl group on both carbon atoms of the double bond. The name stilbene was derived from the Greek word stilbos, which means shining. Many stilbenes and their derivates (stilbenoids) are naturally present in plants (dietary fruits or herbs). Resveratrol Potential neuroprotective eects. The most widely investigated stilbene is resveratrol (3, 4, 5-transtrihydroxystilbene, RES, Figure 3), a phytoalexin found in plants such as grapes, peanuts, berries, and pines.96 RES is synthesized in these plants to counteract various environmental injuries, such as UV irradiation and fungal infection. RES is reported to be one of the active agents in Itadori tea, which has been used as a traditional medicine in China and Japan, mainly for treating heart disease and stroke.97 Epidemiological studies reporting the inverse
Nutrition Reviews Vol. 70(7):373386

be a more eective neuroprotective agent. OXY is found in the heartwood or fruit of Artocarpus heterophyllus, Artocarpus lakoocha, Artocarpus gomezianus, and Artocarpus dadah, in the wood or fruit of mulberry trees (Morus australis, Morus alba L.), in the fruit of Melaleuca leucadendron, in rhizomes of Smilacis chinae, and in the Egyptian herb Schoenocaulon ocinale. Mechanisms of action. In vivo and in vitro studies have shown anti-inammatory eects of OXY, particularly OXY isolated from Artocarpus heterophyllus, Artocarpus dadah, or mulberry wood.108,109 OXY can also reduce the production of beta-amyloid by inhibiting b-secretase 1.110 OXY has been demonstrated to protect against 6-OHDAinduced toxicity in SH-SY5Y cells by reducing the release of lactate dehydrogenase and caspase-3 specic activity.111 Analysis by high-performance liquid chromatography showed that OXY readily penetrates into neurons, thereby suppressing the level of intracellular ROS by its potent free-radical-scavenging activity. OXY was also found to upregulate SIRT1 levels, indicating that the neuroprotective properties of SIRT1 may be attributable to its activation.111 PHYTOESTROGENS It has been known that the incidence of PD is lower in women than in men (using age controls), indicating a protective eect of estrogen or its derivatives.112 The incidence of PD is also lower in premenopausal women than in postmenopausal women.113 The neuroprotective eects of estrogen have been shown in many studies, including upregulation of Bcl-2 and brain-derived neurotrophic factor.114 However, numerous side eects discourage women from receiving hormone replacement therapy. Phytoestrogens, obtained through either the diet or supplements, provide an alternative to traditional hormone replacement therapy without some of the reported side eects; this will be discussed in the following section. Phytoestrogens are a group of substances that are found naturally in plants and possess a common chemical structure similar to that of estradiol. Major food sources of phytoestrogens include soy products, nuts, and grains. Two types of phytoestrogens are discussed below. Ginsenoside Rg1 Oxyresveratrol Potential neuroprotective eect. Recent studies have found that RES may not be the most eective neuroprotective agent. Investigations on the dierential bioactivities of RES and oxyresveratrol (OXY) (2, 3, 4, 5-trans-trihydroxystilbene, Figure 3) have shown OXY to
Nutrition Reviews Vol. 70(7):373386

Figure 3 Chemical structure of (a) trans-resveratrol and (b) trans-oxyresveratrol. association between moderate consumption of red wine and the incidence of coronary heart disease have stimulated investigations on the cardioprotective activity of RES.98 In recent years, numerous studies have shown that RES can protect dopaminergic neurons against toxicity induced by LPS, DA, or MPP+.99101 The neuroprotective eects of RES have also been reported in 6-OHDAlesioned rats and in mouse models of MPTP-induced neuronal loss.102,103 Mechanisms of action. The underlying mechanisms of neuroprotection by RES include the inhibition of NADPH oxidase and the suppression of proinammatory genes such as interleukin 1-a and tumor necrosis factor-a triggered by LPS.99,104 Pretreatment with RES reduced apoptosis in PC12 cells by modulating mRNA levels and protein expression levels of BAX and Bcl-2 in vitro.100 RES may stimulate SIRT1 in 6-OHDA-triggered SK-N-BE cells, as indicated by the loss of protection in the presence of the SIRT1 inhibitor sirtinol, a loss that also occurred when SIRT1 expression was downregulated by siRNA approach.105107 In addition, RES exhibits neuroprotective eects on MPTP-induced motor coordination impairment, hydroxyl radical overloading, and neuronal loss through free-radical-scavenging activity.102

Potential neuroprotective eects. Ginsenosides are a class of molecules extracted from several species of ginseng. Ginseng has a long history in traditional Chinese medicine, Indian herbal medicine, and the medicine of other Asian cultures, and it is well known for its antiaging eects. Rg1 is a ginsenoside isolated from the root of
381

Rg1 is also benecial to the maintenance of mitochondrial functions. In the presence of rotenone, Rg1 restored depleted mitochondrial membrane potential.117 Antiapoptotic eects included inhibition of cytochrome c release and activation of the PI3K/Akt cell survival pathway, resulting in enhanced inhibition of Bad protein expression.117 Upon blocking the glucocorticoid receptor with an antagonist, these eects were blocked, indicating that Rg1 mediates its eects through the glucocorticoid receptor.117 Genistein Potential neuroprotective eects. Soy and peanuts are rich dietary sources of the phytoestrogen genistein, which has been found to be the primary circulating soy isoavone (Figure 4).123 In fact, dietary soy is widely used as an alternative to traditional hormonal replacement therapy. In 2007, a study was conducted by Azadbakht et al. 124 to nd the eects of dietary soy on postmenopausal women with metabolic syndrome. Compared with normal subjects, the postmenopausal women had reduced plasma levels of malondialdehyde, an oxidative stress marker. Numerous studies in rats have shown that treatment with genistein isolated from plant sources results in similar antioxidative eects and antiapoptotic eects. Mechanisms of action. Many studies have shown that genistein binds to estrogen receptors in the central nervous system. The estrogen receptor b has been found to have a particularly high binding anity for genistein.125 Upon binding to the estrogen receptor, the genisteinreceptor complex acts as a transcriptional activator to upregulate antioxidative and antiapoptotic genes.123,126 The antioxidative eects of genistein have been attributed to its ability to increase the levels of malondialdehyde, superoxide dismutase, and monoamine oxidase.124,127 On the other hand, Kaul et al. 128 concluded that genistein specically attenuated the generation of ROS, but not oxidative stress.128 They conducted an experiment testing the eect of genistein on hydrogen-peroxideinduced cell death in rat mesencephalic dopaminergic neurons known as N27 cells. While no antioxidative mechanism was suggested, the authors showed that genistein acted as a tyrosine kinase inhibitor, thereby attenuating the activation of protein kinase C gamma and its downstream proapoptotic eects.128 In addition, it has been proposed that genistein may be able to regulate activity of dopaminergic neurons because estradiol has been shown to play a role in regulation of the neurotransmitter in animal studies.125 A recent study testing the eects of genistein treatment prior to intrastriatal 6-OHDA lesions in rats is in line with this hypothesis. It was found that genistein pretreatment
Nutrition Reviews Vol. 70(7):373386

Figure 4 Chemical structure of (a) ginsenoside Rg1 and (b) genistein.

Panax ginseng. It is one of the relatively well-studied ginsenosides (Figure 4). In vivo, Rg1 can attenuate 6-OHDA neurotoxicity, MPTP-induced neurotoxicity, and oxidative stress.112,115 It can also suppress tumor proliferation.116 In vitro studies have shown that Rg1 can attenuate rotenone toxicity.117 Mechanisms of action. Ginsenoside Rg1 has been found to regulate several signaling pathways, which may explain its neuroprotective eects. The signaling pathways modulated by ginsenoside Rg1 include PI3K/Akt, ERK, JNK, ROS-NFkB, IGF-1 receptor signaling pathways, and estrogen receptor pathway.115,118120 In 2005, Chen et al. 115 tested the eects of Rg1 against MPTP-induced neurotoxicity in mice. Results showed that Rg1 was able to reduce neuronal loss caused by MPTP toxicity through two possible mechanisms. First, Rg1 prevented the reduction of glutathione. Second, Rg1 attenuated phosphorylation of c-Jun, as JNK signaling can be proapoptotic.115,121 A third mechanism was proposed by Wang et al.122 in 2009. By iron staining, the authors showed, in a mouse model of MPTP toxicity, that elevated iron levels in the SN were linked to neuronal death. Rg1 prevented this elevation of iron levels by regulating the expression of iron transport proteins such as ferroportin 1 and divalent metal transport 1.122
382

attenuated rotational behavior in rats, a symptom of parkinsonism.126 POTENTIAL APPLICATIONS OF NUTRACEUTICALS IN CURRENT PD THERAPY The potential benets of nutraceuticals in PD may extend from prevention to the delay of disease progression. Furthermore, dietary supplements or functional foods may reduce the side eects of current treatments or enhance the bioavailability of L-dopa. B vitamins and hyperhomocysteinemia Numerous studies have demonstrated that treatment with L-dopa in PD patients induces high levels of homocysteine (HHcy). Studies show that HHcy is a substantial risk factor for cardiovascular, cerebrovascular, and peripheral vascular diseases as well as cognitive impairment and dementia.129 L-dopa administered to PD patients is metabolized to 3-O-methyl-dopa via methlyation by COMT in peripheral tissues. S-adenosyl-methionine (SAM) provides the methyl group in the reaction and is converted to S-adenosyl-homocysteine (SAH) after donation of the methyl group to L-dopa. Subsequent metabolic reactions metabolize SAH to HHcy, resulting in increased levels of HHcy in plasma.130 It is well recognized that high levels of HHcy can be caused by deciencies in any one of the three important B vitamins, namely, folate, vitamin B12, and vitamin B6, 129 because HHcy can be catabolized to cysteine by a chain reaction in which vitamin B6 acts as a cofactor, while methionine synthase, an enzyme using vitamin B12 as a cofactor, and 5-methyltetrahydrofolate can also metabolize HHcy to methionine.130 Reports have shown that PD patients treated with L-dopa exhibit higher HHcy levels in plasma, but a signicant reduction in HHcy levels was observed in PD patients supplemented with folate, vitamin B12, and vitamin B6. Therefore, supplementation with these vitamins is important for managing the elevated HHcy levels in PD patients.129,131 Vitamin C, hydrosoluble ber, and pharmacokinetics Although ndings about the ecacy of the neuroprotective eects of vitamin C were inconclusive, vitamin C may improve the ecacy of L-dopa. In a pharmacokinetic study, vitamin C was found to enhance absorption of L-dopa in elderly patients with PD.132 Another study using water-soluble ber of Plantago ovata husk showed that treatment of the plant with L-dopa/carbidopa benets PD patients by relieving constipation and improving the L-dopa prole.133 These studies suggest
Nutrition Reviews Vol. 70(7):373386

that functional foods can help patients via augmentation with drug therapy.

CONCLUSION The relationship between diet and disease prevention is not a new concept. In fact, the basic theory in Chinese herbal medicine, medicine and diet share the same origins, emphasizes that scientic diet strategy may play an undeniable role in human health. One after another, studies have shown the importance of a nutritious diet and active lifestyle as a healthy aging strategy in the prevention of most aging-related diseases, such as cancer, cardiovascular disease, and neurodegenerative diseases. In fact, many populations worldwide have embraced this concept for generations and have incorporated various kinds of nutraceuticals in their diet. Not only should this concept be encouraged as part of daily living to prevent disease, it should also be promoted and applied in a clinical setting. Nutraceuticals and diet strategies do more than just improve the quality of life for patients.As discussed, when applied in combination with L-dopa drug therapy, B-complex vitamins and vitamin C have positive eects, including reduced side eects and enhanced absorption of L-dopa. These nutraceuticals enhance the eect of contemporary drug therapy and may allow for an attenuated drug dosage, further reducing any dose-dependent side eects. There is much potential in the positive synergistic eects between nutraceuticals and clinical drug therapy. Hence, instead of identifying the neuroprotective eects of nutraceuticals alone, future research should focus on the eects of nutraceuticals in combination with drug therapy. Furthermore, enhanced drug therapy may be developed through design and application of co-drugs linking nutraceuticals and therapeutic drugs, e.g., by linking stilbene compounds to L-dopa or even by linking curcuminoids to L-dopa. This strategy of linking nutraceuticals to drugs may contribute to new drug designs as well as to more well-designed experimental studies and clinical trials. Nutraceuticals, though attractive and benecial, are still not the cure for PD. Experimental evidence is too limited to enable the development of eective drugs from nutraceuticals. Well-designed and placebo-controlled human intervention trials are undoubtedly required to conrm experimental ndings. Many of the nutraceuticals discussed in this review have been shown to be not only preventative but also therapeutic for PD. Nonetheless, there are still many unknowns, especially with regard to the pharmacokinetics and pharmacodynamics of these nutraceuticals, the eective intake dosage, and the exact therapeutic target, all of which hinders their usage in a
383

clinical setting. High-quality research is needed to promote the entry of more nutraceuticals into therapeutic usage. Acknowledgments Nutraceutical research in PD in this laboratory is supported by HKU Seed Funding for Applied Research (200907162006) and HKU Strategic Research Theme on Drug Discovery. Declaration of interest. The authors have no relevant interests to declare. REFERENCES
1. Twelves D, Perkins KS, Counsell C. Systematic review of incidence studies of Parkinsons disease. Mov Disord. 2003;18:1931. 2. Frigerio R, Sanft KR, Grossardt BR, et al. Chemical exposures and Parkinsons disease: a population-based case-control study. Mov Disord. 2006;21:1688 1692. 3. Ascherio A, Chen H, Weisskopf MG, et al. Pesticide exposure and risk for Parkinsons disease. Ann Neurol. 2006;60:197203. 4. Cicchetti F, Lapointe N, Roberge-Tremblay A, et al. Systemic exposure to paraquat and maneb models early Parkinsons disease in young adult rats. Neurobiol Dis. 2005;20:360371. 5. Fahn S. Parkinsons disease: 10 years of progress, 19972007. Mov Disord. 2010;25(Suppl 1):S2S14. 6. Schapira AH, Agid Y, Barone P, et al. Perspectives on recent advances in the understanding and treatment of Parkinsons disease. Eur J Neurol. 2009;16: 10901099. 7. Forloni G, Terreni L, Bertani I, et al. Protein misfolding in Alzheimers and Parkinsons disease: genetics and molecular mechanisms. Neurobiol Aging. 2002;23:957976. 8. Martinez-Vicente M, Cuervo AM. Autophagy and neurodegeneration: when the cleaning crew goes on strike. Lancet Neurol. 2007;6:352361. 9. Rubinsztein DC. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature. 2006;443:780786. 10. Halliwell B. Oxidative stress and neurodegeneration: where are we now? J Neurochem. 2006;97:16341658. 11. Youdim MB, Riederer P. Understanding Parkinsons disease. Sci Am. 1997;276: 5259. 12. Castellani RJ, Perry G, Siedlak SL, et al. Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans. Neurosci Lett. 2002;319:2528. 13. Sudha K, Rao AV, Rao S, et al. Free radical toxicity and antioxidants in Parkinsons disease. Neurol India. 2003;51:6062. 14. Perier C, Bove J, Wu DC, et al. Two molecular pathways initiate mitochondriadependent dopaminergic neurodegeneration in experimental Parkinsons disease. Proc Natl Acad Sci U S A. 2007;104:81618166. 15. Beal MF. Mitochondria, oxidative damage, and inammation in Parkinsons disease. Ann N Y Acad Sci. 2003;91:120131. 16. Hartmann A, Hunot S, Michel PP, et al. Caspase-3: a vulnerability factor and nal eector in apoptotic death of dopaminergic neurons in Parkinsons disease. Proc Natl Acad Sci U S A. 2000;97:28752880. 17. Langston JW, Ballard P, Tetrud JW, et al. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219:979980. 18. Reichmann H, Janetzky B. Mitochondrial dysfunction a pathogenetic factor in Parkinsons disease. J Neurol. 2000;247(Suppl 2):II63II68. 19. Lambert AJ, Brand MD. Reactive oxygen species production by mitochondria. Methods Mol Biol. 2009;554:165181. 20. Emborg ME. Evaluation of animal models of Parkinsons disease for neuroprotective strategies. J Neurosci Methods. 2004;139:121143. 21. Liu J, Ames BN. Reducing mitochondrial decay with mitochondrial nutrients to delay and treat cognitive dysfunction, Alzheimers disease, and Parkinsons disease. Nutr Neurosci. 2005;8:6789. 22. Khrapko K, Vijg J. Mitochondrial DNA mutations and aging: devils in the details? Trends Genet. 2009;25:9198. 23. Trifunovic A, Larsson NG. Mitochondrial dysfunction as a cause of ageing. J Intern Med. 2008;263:167178.

24. Fato R, Bergamini C, Leoni S, et al. Generation of reactive oxygen species by mitochondrial complex I: implications in neurodegeneration. Neurochem Res. 2008;33:24872501. 25. Chaturvedi RK, Shukla S, Seth K, et al. Neuroprotective and neurorescue eect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinsons disease. Neurobiol Dis. 2006;22:421434. 26. Maxwell SRJ. Antioxidant vitamin supplements: update of their potential benets and possible risks. Drug Saf. 1999;21:253266. 27. Anderson C, Checkoway H, Franklin GM, et al. Dietary factors in Parkinsons disease: the role of food groups and specic foods. Mov Disord. 1999;14:2127. 28. Fahn S. An open trial of high-dosage antioxidants in early Parkinsons disease. Am J Clin Nutr. 1991;53:S380S382. 29. Martin A, Youdim K, Szprengiel A, et al. Roles of vitamins E and C on neurodegenerative diseases and cognitive performance. Nutr Rev. 2002;60:308326. 30. The Parkinson Study Group. Eects of tocopherol and deprenyl on the progression of disability in early Parkinsons disease. N Engl J Med. 1993;328: 176183. 31. Olanow CW. Dietary vitamin E and Parkinsons disease: something to chew on. Lancet Neurol. 2003;2:74. 32. Zhang SM, Hernan MA, Chen H, et al. Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology. 2002;59:11611169. 33. Etminan M, Gill SS, Samii A. Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinsons disease: a meta-analysis. Lancet Neurol. 2005;4:362365. 34. Scheider WL, Hershey LA, Vena JE, et al. Dietary antioxidants and other dietary factors in the etiology of Parkinsons disease. Mov Disord. 1997;12:190196. 35. Verhagen H, Buijsse B, Jansen E, et al. The state of antioxidant aairs. Nutr Today. 2006;41:244250. 36. Newmark HL, Newmark J. Vitamin D and Parkinsons disease a hypothesis. Mov Disord. 2007;22:461468. 37. Wang JY, Wu JN, Cherng TL, et al. Vitamin D attenuates 6-hydroxydopamineinduced neurotoxicity 3 in rats. Brain Res. 2001;904:6775. 38. Shinpo K, Kikuchi S, Sasaki H, et al. Eect of 1,25-dihydroxyvitamin D3 on cultured mesencephalic dopaminergic neurons to the combined toxicity caused by L-buthionine sulfoximine and 1-methyl-4-phenylpyridine. J Neurosci Res. 2000;62:374382. 39. Zhang J, Sokal I, Peskind ER, et al. CSF multianalyte prole distinguishes Alzheimer and Parkinson diseases. Clin Chem. 2008;129:526529. 40. Knekt P, Kilkkinen A, Rissanen H, et al. Serum vitamin D and the risk of Parkinson disease. Arch Neurol. 2010;67:808811. 41. Kirik D, Georgievska B, Rosenblad C, et al. Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinsons disease. Eur J Neurosci. 2001;13:15891599. 42. Garcion E, Wion-Barbot N, Montero-Menei CN, et al. New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab. 2002;13:100105. 43. Evatt ML, Delong MR, Khazai N, et al. Prevalence of vitamin D insuciency in patients with Parkinson disease and Alzheimer disease. Arch Neurol. 2008;65: 13481352. 44. Shults CW. Therapeutic role of coenzyme Q(10) in Parkinsons disease. Pharmacol Ther. 2005;107:120130. 45. Beal MF, Matthews RT, Tieleman A, et al. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res. 1998;783:109114. 46. Cleren C, Yang L, Lorenzo B, et al. Therapeutic eects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism. J Neurochem. 2008; 104:16131621. 47. Shults CW, Oakes D, Kieburtz K, et al. Eects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002; 59:15411550. 48. Muller T, Buttner T, Gholipour AF, et al. Coenzyme Q10 supplementation provides mild symptomatic benet in patients with Parkinsons disease. Neurosci Lett. 2003;341:201204. 49. Bonakdar RA, Guarneri E. Coenzyme Q10. Am Fam Physician. 2005;72:1065 1070. 50. Shults CW, Haas RH, Beal MF. A possible role of coenzyme Q10 in the etiology and treatment of Parkinsons disease. Biofactors. 1999;9:267272. 51. Matthews RT, Ferrante RJ, Klivenyi P, et al. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol. 1999;157:142149. 52. Bender A, Koch W, Elstner M, et al. Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology. 2006;67:1262 1264. 53. Beal MF. Therapeutic approaches to mitochondrial dysfunction in Parkinsons disease. Parkinsonism Relat Disord. 2009;15(Suppl 3):S189S194. 54. Valastro B, Dekundy A, Danysz W, et al. Oral creatine supplementation attenuates L-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned rats. Behav Brain Res. 2009;197:9096. 55. de Lau LM, Bornebroek M, Witteman JC, et al. Dietary fatty acids and the risk of Parkinson disease: the Rotterdam Study. Neurology. 2005;64:20402045. 56. Chen H, Zhang SM, Hernan MA, et al. Dietary intakes of fat and risk of Parkinsons disease. Am J Epidemiol. 2003;157:10071014.

384

Nutrition Reviews Vol. 70(7):373386

57. Bousquet M, Saint-Pierre M, Julien C, et al. Benecial eects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinsons disease. FASEB J. 2008;22:12131225. 58. Fernstrom JD. Can nutrient supplements modify brain function? Am J Clin Nutr. 2000;71:S1669S1675. 59. Kris-Etherton PM, Pearson TA, Wan Y, et al. High-monounsaturated fatty acid diets lower both plasma cholesterol and triacylglycerol concentrations. Am J Clin Nutr. 1999;70:10091015. 60. Garcia-Arencibia M, Garcia C, Fernandez-Ruiz J. Cannabinoids and Parkinsons disease. CNS Neurol Disord Drug Targets. 2009;8:432439. 61. Julien C, Berthiaume L, Hadj-Tahar A, et al. Postmortem brain fatty acid prole of levodopa-treated Parkinson disease patients and parkinsonian monkeys. Neurochem Int. 2006;48:404414. 62. Manyam BV. Paralysis agitans and levodopa in Ayurveda: ancient Indian medical treatise. Mov Disord. 1990;5:4748. 63. Manyam BV, Sanchez-Ramos JR. Traditional and complementary therapies in Parkinsons disease. Adv Neurol. 1999;80:565574. 64. Vaidya AB, Rajagopalan TG, Mankodi NA, et al. Treatment of Parkinsons disease with the cowhage plant Mucuna pruriens Bak. Neurol India. 1978;26:171176. 65. Nagashayana N, Sankarankutty P, Nampoothiri MR, et al. Association of L-dopa with recovery following Ayurveda medication in Parkinsons disease. J Neurol Sci. 2000;176:124127. 66. HP200 in Parkinsons Disease Study Group. An alternative medicine treatment for Parkinsons disease: results of a multicenter clinical trial. J Altern Complement Med. 1995;1:249255. 67. Katzenschlager R, Evans A, Manson A, et al. Mucuna pruriens in Parkinsons disease: a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry. 2004;75:16721677. 68. Manyam BV, Dhanasekaran M, Hare TA. Neuroprotective eects of the antiparkinson drug Mucuna pruriens. Phytother Res. 2004;18:706712. 69. Tharakan B, Dhanasekaran M, Mize-Berge J, et al. Anti-Parkinson botanical Mucuna pruriens prevents levodopa induced plasmid and genomic DNA damage. Phytother Res. 2007;21:11241126. 70. Spencer JP, Jenner A, Aruoma OI, et al. Intense oxidative DNA damage promoted by L-dopa and its metabolites. Implications for neurodegenerative disease. FEBS Lett. 1994;353:246250. 71. Urquiaga I, Leighton F. Plant polyphenol antioxidants and oxidative stress. Biol Res. 2000;33:5564. 72. Pan T, Jankovic J, Le W. Potential therapeutic properties of green tea polyphenols in Parkinsons disease. Drugs Aging. 2003;20:711721. 73. Mandel S, Weinreb O, Amit T, et al. Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (-)-epigallocatechin-3-gallate: implications for neurodegenerative diseases. J Neurochem. 2004;88:15551569. 74. Weinreb O, Mandel S, Amit T, Youdim MB. Neurological mechanisms of green tea polyphenols in Alzheimers and Parkinsons diseases. J Nutr Biochem. 2004;15:506516. 75. Levites Y, Weinreb O, Maor G, et al. Green tea polyphenol (-)-epigallocatechin3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem. 2001;78:10731082. 76. Mandel S, Weinreb O, Reznichenko L, et al. Green tea catechins as brainpermeable, non toxic iron chelators to iron out iron from the brain. J Neural Transm Suppl. 2006;71:249257. 77. Guo S, Yan J, Yang T, et al. Protective eects of green tea polyphenols in the 6-OHDA rat model of Parkinsons disease through inhibition of ROS-NO pathway. Biol Psychiatry. 2007;62:13531362. 78. Tan LC, Koh WP, Yuan JM, et al. Dierential eects of black versus green tea on risk of Parkinsons disease in the Singapore Chinese Health Study. Am J Epidemiol. 2008;167:553560. 79. Jagatha B, Mythri RB, Vali S, et al. Curcumin treatment alleviates the eects of glutathione depletion in vitro and in vivo: therapeutic implications for Parkinsons disease explained via in silico studies. Free Radic Biol Med. 2008;44:907 917. 80. Zbarsky V, Datla KP, Parkar S, et al. Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and setin in a 6-OHDA model of Parkinsons disease. Free Radic Res. 2005;39:11191125. 81. Wang J, Du XX, Jiang H, et al. Curcumin attenuates 6-hydroxydopamineinduced cytotoxicity by anti-oxidation and nuclear factor-kappa B modulation in MES23.5 cells. Biochem Pharmacol. 2009;78:178183. 82. Yang S, Zhang D, Yang Z, et al. Curcumin protects dopaminergic neuron against LPS induced neurotoxicity in primary rat neuron/glia culture. Neurochem Res. 2008;33:20442053. 83. Yu S, Zheng W, Xin N, et al. Curcumin prevents dopaminergic neuronal death through inhibition of the c-Jun N-terminal kinase pathway. Rejuvenation Res. 2010;13:5564. 84. Chen J, Tang XQ, Zhi JL, et al. Curcumin protects PC12 cells against 1-methyl4-phenylpyridinium ion-induced apoptosis by bcl-2-mitochondria-ROS-iNOS pathway. Apoptosis. 2006;11:943953. 85. Rajeswari A, Sabesan M. Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model

86.

87. 88.

89.

90. 91.

92.

93.

94.

95.

96. 97. 98. 99.

100.

101. 102.

103.

104.

105.

106. 107.

108.

109.

110. 111. 112.

113.

114.

of Parkinsons disease induced by MPTP neurodegeneration in mice. Inammopharmacology. 2008;16:9699. Wang MS, Boddapati S, Emadi S, et al. Curcumin reduces alpha-synuclein induced cytotoxicity in Parkinsons disease cell model. BMC Neurosci. 2010; 11:57. Pandey N, Strider J, Nolan WC, et al. Curcumin inhibits aggregation of alphasynuclein. Acta Neuropathol. 2008;115:479489. Ortiz-Ortiz MA, Moran JM, Bravosanpedro JM, et al. Curcumin enhances paraquat-induced apoptosis of N27 mesencephalic cells via the generation of reactive oxygen species. Neurotoxicology. 2009;30:10081018. Ortiz-Ortiz MA, Moran JM, Ruiz-Mesa LM, et al. Curcumin exposure induces expression of the Parkinsons disease-associated leucine-rich repeat kinase 2 (LRRK2) in rat mesencephalic cells. Neurosci Lett. 2010;468:120124. van Leyen K, Kim HY, Lee SR, et al. Baicalein and 12/15-lipoxygenase in the ischemic brain. Stroke. 2006;37:30143018. Chen SF, Hsu CW, Huang WH, et al. Post-injury baicalein improves histological and functional outcomes and reduces inammatory cytokines after experimental traumatic brain injury. Br J Pharmacol. 2008;155:12791296. Cheng Y, He G, Mu X, et al. Neuroprotective eect of baicalein against MPTP neurotoxicity: behavioral, biochemical and immunohistochemical prole. Neurosci Lett. 2008;441:1620. Mu X, He G, Cheng Y, et al. Baicalein exerts neuroprotective eects in 6-hydroxydopamine-induced experimental parkinsonism in vivo and in vitro. Pharmacol Biochem Behav. 2009;92:642648. Waxman EA, Emmer KL, Giasson BI. Residue Glu83 plays a major role in negatively regulating a-synuclein amyloid formation. Biochem Bioph Res Commun. 2010;391:14151420. Jiang M, Porat-Shliom Y, Pei Z, et al. Baicalein reduces E46K alpha-synuclein aggregation in vitro and protects cells against E46K alpha-synuclein toxicity in cell models of familiar Parkinsonism. J Neurochem. 2010;114:419429. Fremont L. Biological eects of resveratrol. Life Sci. 2000;66:663673. Burns J, Yokota T, Ashihara H, et al. Plant foods and herbal sources of resveratrol. J Agric Food Chem. 2002;50:33373340. Bhat KPL, Kosmeder JW, Pezzuto JM. Biological eects of resveratrol. Antioxid Redox Signal. 2001;3:10411064. Zhang F, Shi JS, Zhou H, et al. Resveratrol protects dopamine neurons against lipopolysaccharide-induced neurotoxicity through its anti-inammatory actions. Mol Pharmacol. 2010;78:466477. Bournival J, Quessy P, Martinoli MG. Protective eects of resveratrol and quercetin against MPP+ -induced oxidative stress act by modulating markers of apoptotic death in dopaminergic neurons. Cell Mol Neurobiol. 2009;29:1169 1180. Lee MK, Kang SJ, Poncz M, et al. Resveratrol protects SH-SY5Y neuroblastoma cells from apoptosis induced by dopamine. Exp Mol Med. 2007;39:376384. Lu KT, Ko MC, Chen BY, et al. Neuroprotective eects of resveratrol on MPTPinduced neuron loss mediated by free radical scavenging. J Agric Food Chem. 2008;56:69106913. Khan MM, Ahmad A, Ishrat T, et al. Resveratrol attenuates 6-hydroxydopamineinduced oxidative damage and dopamine depletion in rat model of Parkinsons disease. Brain Res. 2010;1328:139151. Bureau G, Longpre F, Martinoli MG. Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinammation. J Neurosci Res. 2008;86:403410. Albani D, Polito L, Batelli S, et al. The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by alphasynuclein or amyloid-beta (1-42) peptide. J Neurochem. 2009;110:14451456. Pallas M, Verdaguer E, Tajes M, et al. Modulation of sirtuins: new targets for antiageing. Recent Pat CNS Drug Discov. 2008;3:6169. Pallas M, Casadesus G, Smith MA, et al. Resveratrol and neurodegenerative diseases: activation of SIRT1 as the potential pathway towards neuroprotection. Curr Neurovasc Res. 2009;6:7081. Fang SC, Hsu CL, Yen GC. Anti-inammatory eects of phenolic compounds isolated from the fruits of Artocarpus heterophyllus. J Agric Food Chem. 2008;56:44634468. Su BN, Cuendet M, Hawthorne ME, et al. Constituents of the bark and twigs of Artocarpus dadah with cyclooxygenase inhibitory activity. J Nat Prod. 2002;65: 163169. Jeon SY, Kwon SH, Seong YH, et al. Beta-secretase (BACE1)-inhibiting stilbenoids from Smilax Rhizoma. Phytomedicine. 2007;14:403408. Chao J, Yu MS, Ho YS, et al. Dietary oxyresveratrol prevents parkinsonian mimetic 6-hydroxydopamine neurotoxicity. Free Radic Biol Med. 2008;45:10191026. Xu L, Chen WF, Wong MS. Ginsenoside Rg1 protects dopaminergic neurons in a rat model of Parkinsons disease through the IGF-I receptor signalling pathway. Br J Pharmacol. 2009;158:738748. Rodriguez-Perez AI, Valenzuela R, Villar-Cheda B, et al. Estrogen and angiotensin interaction in the substantia nigra. Relevance to postmenopausal Parkinsons disease. Exp Neurol. 2010;224:517526. Sawada H, Shimohama S. Estrogens and Parkinson disease: novel approach for neuroprotection. Endocrine. 2003;21:7779.

Nutrition Reviews Vol. 70(7):373386

385

115. Chen XC, Zhou YC, Chen Y, et al. Ginsenoside Rg1 reduces MPTP-induced substantia nigra neuron loss by suppressing oxidative stress. Acta Pharmacol Sin. 2005;26:5662. 116. Ma ZC, Gao Y, Wang YG, et al. Ginsenoside Rg1 inhibits proliferation of vascular smooth muscle cells stimulated by tumor necrosis factor-alpha. Acta Pharmacol Sin. 2006;27:10001006. 117. Leung KW, Yung KKL, Mak NK, et al. Neuroprotective eects of ginsenoside-Rg1 in primary nigral neurons against rotenone toxicity. Neuropharmacology. 2007;52:827835. 118. Gao QG, Chen WF, Xie JX, et al. Ginsenoside Rg1 protects against 6-OHDAinduced neurotoxicity in neuroblastoma SK-N-SH cells via IGF-I receptor and estrogen receptor pathways. J Neurochem. 2009;109:13381347. 119. Ge KL, Chen WF, Xie JX, et al. Ginsenoside Rg1 protects against 6-OHDAinduced toxicity in MES23.5 cells via Akt and ERK signaling pathways. J Ethnopharmacol. 2010;127:118123. 120. Xu H, Jiang H, Wang J, et al. Rg1 protects the MPP+-treated MES23.5 cells via attenuating DMT1 up-regulation and cellular iron uptake. Neuropharmacology. 2010;58:488494. 121. Leppa S, Bohmann D. Diverse functions of JNK signaling and c-Jun in stress response and apoptosis. Oncogene. 1999;18:61586162. 122. Wang J, Xu HM, Yang HD, et al. Rg1 reduces nigral iron levels of MPTP-treated C57BL6 mice by regulating certain iron transport proteins. Neurochem Int. 2009;54:4348. 123. Ma Y, Sullivan JC, Schreihofer DA. Dietary genistein and equol (4`, 7 isoavandiol) reduce oxidative stress and protect rats against focal cerebral ischemia. Am J Physiol Regul Integr Comp Physiol. 2010;299:R871R877. 124. Azadbakht L, Kimiagar M, Mehrabi Y, et al. Dietary soya intake alters plasma antioxidant status and lipid peroxidation in postmenopausal women with the metabolic syndrome. Br J Nutr. 2007;98:807813.

125. Cyr M, Calon F, Morissette M, et al. Estrogenic modulation of brain activity: implications for schizophrenia and Parkinsons disease. J Psychiatry Neurosci. 2002;27:1227. 126. Baluchnejadmojarad T, Roghani M, Nadoushan JMR, et al. Neuroprotective eect of genistein in 6-hydroxydopamine hemi-parkinsonian rat model. Phytother Res. 2009;23:132135. 127. Huang YH, Zhang ZQ. Genistein reduced the neural apoptosis in the brain of ovariectomised rats by modulating mitochondrial oxidative stress. Br J Nutr. 2010;104:17. 128. Kaul S, Anantharam V, Yang Y, et al. Tyrosine phosphorylation regulates the proteolytic activation of protein kinase C in dopaminergic neuronal cells. J Biol Chem. 2005;280:2872128730. 129. Miller JW, Selhub J, Nadeau MR, et al. Eect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology. 2003;60: 11251129. 130. Zesiewicz TA, Wecker L, Sullivan KL, et al. The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: eects of vitamin status. Clin Neuropharmacol. 2006;29:106 111. 131. Lamberti P, Zoccolella S, Armenise E, et al. Hyperhomocysteinemia in L-dopa treated Parkinsons disease patients: eect of cobalamin and folate administration. Eur J Neurol. 2005;12:365368. 132. Nagayama H, Hamamoto M, Ueda M, et al. The eect of ascorbic acid on the pharmacokinetics of levodopa in elderly patients with Parkinson disease. Clin Neuropharmacol. 2004;27:270273. 133. Fernandez N, Carriedo D, Sierra M, et al. Hydrosoluble ber (Plantago ovata husk) and levodopa II: experimental study of the pharmacokinetic interaction in the presence of carbidopa. Eur Neuropsychopharmacol. 2005; 15:505509.

386

Nutrition Reviews Vol. 70(7):373386